Updates on the use of neoadjuvant therapy in borderline resectable pancreatic cancer

Namrata Sonia Chandhok, Muhammad Wasif Saif

Research output: Contribution to journalConference articlepeer-review

2 Scopus citations


Pancreatic cancer is an aggressive and devastating cancer that continues to have high 5-year mortality rates despite advancements in the field. Surgery remains the only curative treatment; however, most patients present with late stage disease deemed unresectable. By refining the resection guidelines to include a borderline resectable group, as well as advancements in neoadjuvant chemotherapy and radiation that improve resectability, we may improve upon outcomes for patients with more invasive disease. Here we summarize and discuss findings presented at the 2014 ASCO Gastrointestinal Cancers Symposium (Abstracts #283, #302, #309, #274, #275, #327) that relate neoadjuvant therapeutic strategies and borderline resectable cancers.

Original languageEnglish (US)
Pages (from-to)91-94
Number of pages4
JournalJournal of the Pancreas
Issue number2
StatePublished - 2014
Externally publishedYes
Event2014 ASCO Gastrointestinal Cancers Symposium - San Francisco, CA, United States
Duration: Jan 16 2014Jan 18 2014


  • Drug therapy
  • General surgery
  • Pancreatic neoplasms
  • S 1 (combination)

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology


Dive into the research topics of 'Updates on the use of neoadjuvant therapy in borderline resectable pancreatic cancer'. Together they form a unique fingerprint.

Cite this